Current Leading Therapies for Multiple Myeloma
Nina Shah, MD, discusses the potential therapies that could emerge in 2022 for multiple myeloma.
EP: 1.Breakthroughs in Therapeutic Options for Relapsed/Refractory Multiple Myeloma
EP: 2.Highlights From the 2021 European Hematology Association Congress on Multiple Myeloma
EP: 3.Upcoming Abstracts on Multiple Myeloma for Presentation at 2021 ASH
EP: 4.Biggest FDA News for Multiple Myeloma in 2021
EP: 5.Treatment Options for Transplant-Eligible Multiple Myeloma
EP: 6.Treatment Options for Transplant-Ineligible Multiple Myeloma
EP: 7.Navigating Individual Treatment for Relapsed/Refractory Multiple Myeloma
EP: 8.Understanding Adverse Events in Multiple Myeloma
EP: 9.BCMA-Directed Agents for Multiple Myeloma
EP: 10.Optimal Therapies for Relapsed/Refractory Multiple Myeloma
EP: 11.Emerging Research and Therapies for Multiple Myeloma
EP: 12.Upcoming Phase 3 Data in Multiple Myeloma
EP: 13.Trials Evaluating Emerging Maintenance Therapy Regimens in Multiple Myeloma
EP: 14.Looking Ahead to the Future of Multiple Myeloma Treatment
EP: 15.Current Leading Therapies for Multiple Myeloma
Nina Shah, MD: Today as we go from 2021 to 2022, I would say the leading therapies for induction therapy for transplant-eligible patients are RVd [lenalidomide (Revlimid), bortezomib (Velcade), and dexamethasone] or daratumumab [Darzalex]–RVd based on the GRIFFIN trial [NCT02874742]. That’s becoming a newer and more used regimen, [although] KRd [carfilzomib (Kyprolis), lenalidomide, and dexamethasone] is still a potential for that. I do think transplant still has a role. This has been supported by the IFM trial [NCT01191060] and more recently, by the FORTE trial [NCT02203643]. For maintenance therapy. The jury’s still out. Lenalidomide does give overall survival advantage but perhaps giving carfilzomib in combination with lenalidomide gives you a longer PFS [progression-free survival] as per the FORTE trial and may be particularly better for high-risk patients.
In the relapsed or refractory setting, [specifically] in the early relapse setting, daratumumab in combination with carfilzomib or isatuximab [Sarclisa] in combination with carfilzomib is a very effective treatment and should be considered in the second line. You can also consider things like daratumumab, pomalidomide [Pomalyst], and dexamethasone. In the late line, we are on the horizon to now embrace the BCMA [B-cell maturation antigen] therapies. Hopefully we’re going to have another CAR T-cell therapy available as well as, in the near future, bispecific T-cell engagers.
